AzTrials
AzTrials

Cerebral Palsy (CP)CP-rESWT-FREQNCT07476690

Effect of rESWT Session Frequency on Spasticity and Function Assessed by Sonoelastography in Children With Cerebral Palsy

A study testing Real radial extracorporeal shock wave therapy (rESWT) and Conventional physical therapy in people with Cerebral Palsy (CP), run by Sisli Hamidiye Etfal Training and Research Hospital at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Spasticity is a major contributor to functional limitations in children with cerebral palsy. Radial extracorporeal shock wave therapy (rESWT) has emerged as a non-invasive method for reducing spasticity; however, the optimal session frequency remains unclear. Read more about this study

Who is it for?
Ages 6 to 14 years
Conditions the study is for
Cerebral Palsy (CP)
What is being tested?
Real radial extracorporeal shock wave therapy (rESWT) and Conventional physical therapy
Type of treatment
Medical device
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
30 participants
Where
1 siteTurkey (Türkiye)
Study dates
15 Nov 2025to 15 Jun 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 to 14 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Children aged 6-14 years diagnosed with cerebral palsy according to the Rosenbaum diagnostic criteria.
  • Gross Motor Function Classification System (GMFCS) level I, II, or III.
  • Modified Ashworth Scale (MAS) score >1 and ≤3 in unilateral or bilateral ankle plantar flexor muscle groups.
  • Presence of a spastic gait pattern characterized by a dynamic component of ankle equinus.

Who cannot join

  • Age younger than 6 years or older than 14 years.
  • Botulinum toxin type A injection or extracorporeal shock wave therapy (ESWT) within 6 months prior to enrollment.
  • Fixed contracture with passive joint range of motion (ROM) <5° in the affected extremity, or significant bone or joint deformity.
  • History of orthopedic surgery (tendon release or transfer, tenotomy, muscle release surgery, arthrodesis) involving the affected extremity.
  • Cognitive or behavioral disorders that would prevent participation in the intervention or assessments.
  • Uncontrolled systemic disease or significant comorbid conditions.
Show all 9Show fewer
  • History of neurosurgical intervention (e.g., selective dorsal rhizotomy, neurectomy).
  • Presence of significant dystonia or severe movement disorder in the extremity to be evaluated.
  • Presence of contraindications for ESWT application in the treatment area, including open skin lesions, skin infection, signs of active inflammation, or history of malignancy; bleeding diathesis, use of anticoagulant therapy, or circulatory problems due to vascular pathology.

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Sisli Hamidiye Etfal Training and Research Hospital

    Istanbul, Istanbul, 34371

Other trials in Turkey (Türkiye)

About this study

Official title: The Effect Of Radial Extracorporeal Shock Wave Therapy (rESWT) Session Frequency For Plantar Flexor Muscle Spasticity On Spasticity, Function, Balance And Muscle Morphology In Children With Cerebral Palsy: A Randomized Controlled Trial Using Sonoelastography

Spasticity is a major contributor to functional limitations in children with cerebral palsy. Radial extracorporeal shock wave therapy (rESWT) has emerged as a non-invasive method for reducing spasticity; however, the optimal session frequency remains unclear. This randomized, assessor-blinded, parallel-group controlled trial investigates the effects of different rESWT session frequencies on spasticity, motor function, balance, pain, and muscle properties in children with cerebral palsy.

Participants are randomly assigned to three groups receiving sham rESWT, one real rESWT session per week combined with sham, or two real rESWT sessions per week, in addition to routine neurological rehabilitation. Outcomes are assessed using clinical scales and ultrasonography-based measures, including shear wave elastography. The study aims to define the dose-response relationship of rESWT and inform optimal treatment protocols in pediatric neurorehabilitation.

Read the detailed description

Cerebral palsy is the most common cause of childhood physical disability, and spasticity represents one of its most prominent and disabling features. Increased muscle tone negatively affects mobility, balance, and functional independence and may lead to secondary musculoskeletal complications. Although pharmacological and surgical interventions are available, there is a growing need for non-invasive, easily applicable, and safe treatment options in pediatric neurorehabilitation. Radial extracorporeal shock wave therapy (rESWT) has gained attention as a promising modality for reducing spasticity and improving muscle properties. Previous studies have demonstrated beneficial effects of rESWT in children with cerebral palsy; however, there is no consensus regarding the optimal treatment frequency and dosing strategy. Determining the most effective session frequency is essential to maximize clinical benefit while minimizing treatment burden. By comparing different rESWT session frequencies, this study aims to define a dose-response relationship and identify the most effective treatment strategy. The findings are expected to contribute to evidence-based optimization of rESWT protocols in pediatric neurorehabilitation and to improve functional outcomes in children with cerebral palsy. This study is designed as a prospective, randomized, double-blind, parallel-group controlled clinical trial conducted at the University of Health Sciences, Sisli Hamidiye Etfal Training and Research Hospital, Department of Physical Medicine and Rehabilitation. Participants are recruited from children presenting to the outpatient clinic who meet the inclusion criteria and none of the exclusion criteria. The study follows a double-blind protocol. Except for the operator delivering the intervention, all individuals involved in the study-including participants and outcome assessors-are blinded to the session type (real versus sham rESWT). This design ensures unbiased outcome assessment and minimizes expectancy effects. All participants continue routine neurological rehabilitation consisting of conventional physical therapy for 60 minutes per session, three sessions per week for 12 weeks. In addition, during the first three weeks, all groups attend the research center two days per week for rESWT or sham procedures combined with standardized stretching. In participants with bilateral plantar flexor spasticity, the lower extremity with the highest initial Modified Ashworth Scale (MAS) score will be taken as the basis for evaluation purposes. However, to preserve functional integrity and avoid ethical concerns, rESWT will be applied equally to both lower extremities. rESWT applications will be carried out targeting the motor end-plate zones located in the proximal one-third of the gastrocnemius muscle belly and the mid-belly region of the soleus muscle. Active and sham applications were performed using the same device, in the same patient position, on the same application area, and for the same duration. In both applications, gel was applied between the applicator head and the skin, and the applicator head was kept in contact with the skin. During sham rESWT, a soft applicator head was used; the applicator was applied with minimal compression on the skin at the lowest pressure level allowed by the device, 0.5 bar. Thus, while maintaining skin contact and physical feedback similar to the active application, the therapeutic shock wave energy transmitted to the tissue was intended to be minimized.

Participants are assigned to one of three parallel groups. Group 1 (Control) receives conventional physical therapy three times per week for 12 weeks (60 minutes per session) and, during the first three weeks, attends the research center twice weekly to receive sham rESWT followed by 20 minutes of stretching on both days, for a total of six sham sessions. Group 2 receives the same conventional physical therapy and, during the first three weeks, attends the research center twice weekly, receiving one session of real rESWT combined with 20 minutes of stretching and one session of sham rESWT combined with 20 minutes of stretching each week (total of three real and three sham sessions). Group 3 receives the same conventional physical therapy and, during the first three weeks, attends the research center twice weekly to receive real rESWT followed by 20 minutes of stretching on both days (total of six real sessions). Real rESWT is delivered using standardized parameters of 5 Hz frequency, 1.5 bar pressure, and 2000 shocks per session.

All clinical and ultrasonographic assessments are performed before exercise and rESWT sessions to avoid acute treatment effects and ensure standardization. Baseline demographic and clinical characteristics are recorded prior to treatment.

Evaluations will be performed at four separate time points: pre-treatment (baseline), at the end of treatment, and at 4 weeks and 12 weeks post-treatment.

  • Spasticity levels will be assessed using the Tardieu Scale, Modified Ashworth Scale (MAS), and passive Range of Motion (PROM) measurements.
  • The Pediatric Berg Balance Scale (PBS) will be used for balance assessment, the Modified Timed Up and Go Test (MTUG) for functional mobility, and the 10-Meter Walk Test (10MWT) for walking speed.
  • For the assessment of spasticity-related pain levels, the Revised Faces Pain Scale (FPS-R), which is appropriate and validated for children, will be used.
  • The mechanical properties of the muscle will be quantitatively evaluated using the Shear Wave Elastography (SWE) method; for the evaluation of muscle morphology, muscle thickness will be measured via ultrasonography, and the Modified Heckmatt Scale (MHS) will be applied to classify muscle structural properties
Being tested
Real radial extracorporeal shock wave therapy (rESWT), Sham radial extracorporeal shock wave therapy (rESWT), Conventional physical therapy
Keywords
Cerebral Palsy, Extracorporeal Shock Wave Therapy, rESWT, Session Frequency, Spasticity, Muscle Stiffness, Physical Function, Balance, Pediatric Rehabilitation, Elastography
Medical subject headings
Cerebral Palsy, Muscle Spasticity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Real radial extracorporeal shock wave therapy (rESWT)Device

    Real radial extracorporeal shock wave therapy is applied to spastic muscles using a radial shock wave device. Treatment is delivered during the first 3 weeks according to group allocation, with either one or two sessions per week. Each session is followed by 20 minutes of stretching.

  • Sham radial extracorporeal shock wave therapy (rESWT)Device

    Sham radial extracorporeal shock wave therapy is administered using the same device and procedure as real rESWT but without therapeutic energy output. Sham treatment is delivered during the first 3 weeks according to group allocation.

  • Conventional physical therapyOther

    Routine neurological rehabilitation consisting of conventional physical therapy tailored to individual goals, provided for 60 minutes per session, 3 sessions per week for 12 weeks.

Study groups in NCT07476690
Study groupRoleWhat they receive
Control (Conventional Physical Therapy + Sham rESWT)Sham comparatorAll participants continue routine neurological rehabilitation consisting of conventional physical therapy (60 minutes per session, 3 sessions per week for 12 weeks) tailored to individual goals. In this control arm, during the first 3 weeks, sham radial extracorporeal shock wave therapy (rESWT) is administered 2 days per week (total 6 sham sessions). Each session is followed by 20 minutes of stretching.
Receives: Device: Sham radial extracorporeal shock wave therapy (rESWT); Other: Conventional physical therapy
1 Real rESWT Session per Week (Real + Sham)ExperimentalAll participants continue routine neurological rehabilitation consisting of conventional physical therapy (60 minutes per session, 3 sessions per week for 12 weeks) tailored to individual goals. During the first 3 weeks, rESWT is delivered 2 days per week using a hybrid schedule: one session per week of real rESWT and one session per week of sham rESWT (total 3 real and 3 sham sessions). Each session is followed by 20 minutes of stretching.
Receives: Device: Real radial extracorporeal shock wave therapy (rESWT); Device: Sham radial extracorporeal shock wave therapy (rESWT); Other: Conventional physical therapy
2 Real rESWT Sessions per Week (Real)ExperimentalAll participants continue routine neurological rehabilitation consisting of conventional physical therapy (60 minutes per session, 3 sessions per week for 12 weeks) tailored to individual goals. During the first 3 weeks, real rESWT is administered 2 days per week (total 6 real sessions). Each session is followed by 20 minutes of stretching.
Receives: Device: Real radial extracorporeal shock wave therapy (rESWT); Other: Conventional physical therapy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change from Baseline in Modified Ashworth Scale Score for Ankle Plantarflexor Spasticity with Knee in Flexed and Extended Positions

    Ankle plantarflexor spasticity of the gastrocnemius-soleus complex in the most affected lower limb is assessed using the Modified Ashworth Scale (MAS) with the knee extended and flexed.

    The MAS is an ordinal scale ranging from 0 to 4 (including grade 1+):

    Grade 0: No increase in muscle tone. Grade 1: Slight increase in muscle tone with a catch and release or minimal resistance at the end of the range of motion.

    Grade 1+: Slight increase in muscle tone manifested by minimal resistance through less than half of the range of motion.

    Grade 2: More marked increase in muscle tone through most of the range of motion, but the affected part is easily moved.

    Grade 3: Considerable increase in muscle tone, making passive movement difficult.

    Grade 4: Affected part rigid in flexion or extension.

    Higher scores indicate greater spasticity severity.

    Measured: Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment, and Week 12 post-treatment

Secondary outcomes (9)
  1. Change from Baseline in Ankle Plantarflexor Spasticity Parameters Assessed by the Tardieu Scale with the Knee Extended and Flexed

    Spasticity of the ankle plantarflexor muscles (gastrocnemius-soleus complex) of the most affected lower limb is assessed using the Tardieu Scale with the knee extended and flexed.

    The following Tardieu parameters are recorded:

    XV1: ankle joint angle measured during slow passive stretch (V1) XV3: ankle joint angle measured during fast passive stretch (V3) Spasticity angle (X): calculated as XV1 - XV3, representing the dynamic component of spasticity Spasticity grade (Y): scored from 0 to 5, reflecting the type of muscle reaction during fast stretch

    Angles are recorded in degrees. Higher spasticity angle and higher Y scores indicate greater spasticity severity.

    Measured: Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment, and Week 12 post-treatment

  2. Change from Baseline in Passive Ankle Dorsiflexion Range of Motion with the Knee Extended and Flexed (Degrees)

    Passive ankle dorsiflexion range of motion of the most affected lower limb is measured using a manual goniometer with the knee extended and flexed.

    Participants are positioned in the supine position, and passive dorsiflexion of the ankle joint is performed by the examiner until maximal range of motion is reached. The goniometer axis is aligned with the ankle joint, and the angle between the foot and the lower leg is recorded in degrees.

    Higher values indicate greater ankle dorsiflexion range of motion.

    Measured: Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment, and Week 12 post-treatment

  3. Change from Baseline in Pediatric Berg Balance Scale Score

    Balance is assessed using the Pediatric Berg Balance Scale, a 14-item functional balance assessment. Total scores range from 0 to 56, with higher scores indicating better balance performance and postural control.

    Measured: Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment, and Week 12 post-treatment

  4. Change from Baseline in Modified Timed Up and Go Test Completion Time

    It is the time measured when an individual is standing, walking 3 m straight, returning to the chair, and sitting. In the study, the you will sit comfortably in a chair without back support and arm support. The time for the test will begin as soon as you get up from the chair and will end after you sit in the chair. If the test is less than 10 seconds, it indicates functional independence, and if it is over 30 seconds, it indicates functional dependence.

    Measured: Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment, and Week 12 post-treatment

  5. Change from Baseline in 10-Meter Walk Test Walking Speed

    The 10-Meter Walk Test is used to assess functional walking capacity and gait speed. During the test, a total walkway of 14 meters is arranged on a flat surface. The first 2 meters are designated as the acceleration phase, the middle 10 meters as the measurement distance, and the final 2 meters as the deceleration phase.The participant is positioned at the starting point and instructed to walk at their usual self-selected pace. Upon the command "Ready - Go," the participant begins walking. Timing starts when the participant reaches the 2-meter mark and stops at the 12-meter mark. The total time required to complete the 10-meter distance is recorded in seconds. Walking speed is subsequently calculated in meters per second (m/s). Lower completion times and higher walking speeds indicate better functional walking performance.

    Measured: Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment, and Week 12 post-treatment

  6. Change from Baseline in Revised Faces Pain Scale Score

    Pain intensity is assessed using the Revised Faces Pain Scale, a visual self-report tool designed for pediatric populations. The scale consists of six facial expressions representing increasing levels of pain intensity. Scores range from 0 to 10 (displayed as 0, 2, 4, 6, 8, and 10), where 0 indicates no pain and 10 indicates very severe pain. Higher scores reflect greater pain intensity.

    Measured: Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment, and Week 12 post-treatment

  7. Change from Baseline in Intramuscular Stiffness of the Gastrocnemius-Soleus Complex Assessed by Shear Wave Elastography (kPa)

    Intramuscular stiffness of the gastrocnemius-soleus complex in the most affected lower limb is quantitatively assessed using shear wave elastography (SWE) with a high-resolution ultrasound system.

    Measurements are obtained from the medial gastrocnemius, lateral gastrocnemius, and soleus muscles with the participant in the prone position, knees extended, and ankles maintained in the anatomical neutral resting position. The ultrasound probe is placed parallel to the muscle fibers at the motor end-plate region.

    Three consecutive measurements are recorded for each muscle, and the mean value is used for analysis. Muscle stiffness is expressed as the elastic modulus in kilopascals (kPa).

    Higher values indicate greater muscle stiffness.

    Measured: Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment, and Week 12 post-treatment

  8. Change from Baseline in Muscle Thickness of the Gastrocnemius-Soleus Complex Measured by Ultrasonography (mm)

    Muscle thickness of the gastrocnemius-soleus complex in the most affected lower limb is measured using B-mode ultrasonography.

    Participants are positioned in the prone position, with the knees extended and the ankles maintained in the neutral resting position. Measurements are obtained along the longitudinal axis of the muscle fibers at the anatomically thickest region corresponding to the motor end-plate area.

    For the gastrocnemius muscles, measurements are taken from the proximal one-third of the lower leg, while the soleus muscle is measured from the proximal one-third of the medial lower leg.

    The ultrasound probe is placed with minimal pressure to avoid tissue compression. The distance between the superficial and deep muscle fasciae is measured in millimeters (mm).

    Three consecutive measurements are recorded for each muscle, and the mean value is used for analysis.

    Higher values indicate greater muscle thickness

    Measured: Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment, and Week 12 post-treatment

  9. Change from Baseline in Muscle Echogenicity of the Gastrocnemius-Soleus Complex Assessed by the Modified Heckmatt Scale

    Muscle echogenicity of the gastrocnemius-soleus complex in the most affected lower limb is evaluated using the Modified Heckmatt Scale, a 4-point grading system used in neuromuscular ultrasound.

    Grade 1: Normal muscle echogenicity with clear distinction from bone echo. Grade 2: Increased echogenicity in approximately 10-50% of the muscle tissue, with preserved distinction from bone echo.

    Grade 3: Increased echogenicity in approximately 50-90% of the muscle tissue with reduced differentiation from bone.

    Grade 4: Increased echogenicity in more than 90% of the muscle tissue with loss of distinction from bone.

    Higher grades indicate greater pathological changes and increased muscle echogenicity.

    Measured: Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment, and Week 12 post-treatment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Mar 2026
  2. Study start15 Nov 2025
  3. Primary completion1 Mar 2026
  4. Study completion15 Jun 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Participants are randomly assigned to three parallel groups receiving radial extracorporeal shock wave therapy (rESWT) with different session frequencies (real or sham), in addition to routine neurological rehabilitation. Participants remain in their assigned group throughout the study. The therapist delivering the intervention is not involved in outcome assessments.
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
30 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07476690
Sponsor's protocol ID
CP-rESWT-SessionFreq-RCT-TR-01
Other IDs
2024-KAEK-31
Acronym
CP-rESWT-FREQ
Status last verified
Mar 2026
First submitted
10 Feb 2026
Last updated
5 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Individual participant data will not be shared because the study involves pediatric patients and contains sensitive clinical and imaging data. Data are collected under local ethics committee approval and are intended to be used only for the predefined research objectives. To protect participant privacy and confidentiality, no individual-level data will be made publicly available.

Publications

  • de Roo EG, Koopman SB, Janssen TW, Aertssen WFM. The effects of extracorporeal shock wave therapy in children with cerebral palsy: a systematic review. Int J Surg. 2025 Apr 1;111(4):2773-2790. doi: 10.1097/JS9.0000000000002251.

    PubMed 39878070
  • Chang MC, Choo YJ, Kwak SG, Nam K, Kim SY, Lee HJ, Kwak S. Effectiveness of Extracorporeal Shockwave Therapy on Controlling Spasticity in Cerebral Palsy Patients: A Meta-Analysis of Timing of Outcome Measurement. Children (Basel). 2023 Feb 9;10(2):332. doi: 10.3390/children10020332.

    PubMed 36832460
  • Kwon DR, Kwon DG. Botulinum Toxin a Injection Combined with Radial Extracorporeal Shock Wave Therapy in Children with Spastic Cerebral Palsy: Shear Wave Sonoelastographic Findings in the Medial Gastrocnemius Muscle, Preliminary Study. Children (Basel). 2021 Nov 17;8(11):1059. doi: 10.3390/children8111059.

    PubMed 34828772

Questions about this trial

What is this clinical trial studying?

A study testing Real radial extracorporeal shock wave therapy (rESWT) and Conventional physical therapy in people with Cerebral Palsy (CP), run by Sisli Hamidiye Etfal Training and Research Hospital at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 5 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change from Baseline in Modified Ashworth Scale Score for Ankle Plantarflexor Spasticity with Knee in Flexed and Extended Positions (time frame: Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment, and Week 12 post-treatment). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07476690, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Aug 2026; AzTrials last refreshed its copy on 27 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in